中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2042-2048

Differences and application value of plasma bile acids in tumors of the liver

DOI: 10.12449/JCH241018
  • 1a.

    Department of Oncology，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 1b.

    Technical Experimental Center，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2a.

    School of Integrative Medicine，Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2b.

    Institute of Liver Diseases，Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 3.

    Shanghai Key Laboratory of Traditional Chinese Medicine，Shanghai 201203，China

  • 4.

    Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China

Research funding:

National Natural Science Foundation of China (82104619);

Shanghai Municipal Health Commission Health Industry Clinical Research Project (20214Y0455);

Project under Budget of Shanghai University of Traditional Chinese Medicine (2021LK105)

More Information
  • Corresponding author: FENG Qin， fengqin@shutcm.edu.cn （ORCID： 0000-0002-4641-1636）
  • Received Date: 2024-01-24
  • Accepted Date: 2024-04-15
  • Published Date: 2024-10-25
    Abstract
  •   Objective  To investigate the levels of plasma bile acids （BA） in patients with primary liver cancer （PLC） or metastatic liver cancer （MLC） and their correlation with clinical indicators， as well as the value of plasma BAs combined with alpha-fetoprotein （AFP） in the diagnosis of PLC.  Methods  This study was conducted among 75 patients with PLC and 79 patients with MLC who attended Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2020 to September 2021 and had a confirmed diagnosis based on histopathological and imaging findings. Peripheral blood samples were collected from all patients， and serum and plasma were separated. Colorimetry and chromatography were used to measure biochemical parameters； electrochemiluminescence immunoassay was used to measure the levels of tumor markers； liquid chromatography-tandem mass spectrometry was used to measure the content of BA. The t-test was used for comparison of normally distributed continuous data， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data； the Spearman’s coefficient was used for correlation analysis； the receiver operating characteristic （ROC） curve was used to evaluate clinical diagnostic efficacy.  Results  The PLC group had significantly lower levels of total cholesterol， triglyceride， low-density lipoprotein cholesterol， and apolipoprotein B than the MLC group （U=1 598， 1 255， 909， and 889， all P<0.05）. Compared with the MLC group， the PLC group had a significantly higher level of AFP and a significantly lower level of carcinoembryonic antigen （U=1 873 and 926， both P<0.05）. Compared with the MLC group， the PLC group had significantly higher levels of TBA， CA， CDCA， UDCA， TCA， TCDCA， GCA， GCDCA， TUDCA， and GUDCA and a significantly lower level of DCA （all P<0.05）. In the total population， the levels of TBA， CDCA， GCA， GCDCA， GUDCA， TCA， TCDCA， and TUDCA were significantly positively correlated with the level of AFP （all P<0.05）. In the patients with PLC， the levels of GCA， TCA， TCDCA， and TUDCA were significantly positively correlated with the level of AFP （all P<0.05）. Combined measurement of AFP+TCA+GCA+TCDCA had an area under the ROC curve of 0.822 （95% confidence interval： 0.746‍ ‍—‍ ‍0.898， P<0.000 1）， suggesting that it had the highest diagnostic efficacy.  Conclusion  There are significant differences in the levels of plasma BA between the patients with PLC and those with MLC， and the differentially expressed BAs are closely associated with liver function impairment and the increase in AFP. BAs combined with AFP has a better clinical value in the diagnosis of PLC.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    JIA W, XIE GX, JIA WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 2): 111- 128. DOI: 10.1038/nrgastro.2017.119.
    [2]
    CHÁVEZ-TALAVERA O, TAILLEUX A, LEFEBVRE P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 7): 1679- 1694.e3. DOI: 10.1053/j.gastro.2017.01.055.
    [3]
    SMIRNOVA E, MUTHIAH MD, NARAYAN N, et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD[J]. Hepatology, 2022, 76( 6): 1811- 1824. DOI: 10.1002/hep.32568.
    [4]
    CHEN T, WANG L, XIE G, et al. Serum bile acids improve prediction of Alzheimer's progression in a sex-dependent manner[J]. Adv Sci(Weinh), 2024, 11( 9): e2306576. DOI: 10.1002/advs.202306576.
    [5]
    SONG WS, PARK HM, HA JM, et al. Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma[J]. Sci Rep, 2018, 8( 1): 11088. DOI: 10.1038/s41598-018-29445-z.
    [6]
    JI SY, LIU QX, ZHANG SH, et al. FGF15 activates hippo signaling to suppress bile acid metabolism and liver tumorigenesis[J]. Dev Cell, 2019, 48( 4): 460- 474. e 9. DOI: 10.1016/j.devcel.2018.12.021.
    [7]
    SUN RQ, ZHANG ZY, BAO RX, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis[J]. J Hepatol, 2022, 77( 2): 453- 466. DOI: 10.1016/j.jhep.2022.02.030.
    [8]
    LIU ZR, JIA XD, LU YY. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. J Clin Hepatol, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038.

    刘哲睿, 贾晓东, 陆荫英. 肝细胞癌相关胆汁酸代谢失衡及调控机制的研究进展[J]. 临床肝胆病杂志, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038.
    [9]
    SYDOR S, BEST J, MESSERSCHMIDT I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC[J]. Clin Transl Gastroenterol, 2020, 11( 3): e00131. DOI: 10.14309/ctg.0000000000000131.
    [10]
    PETRICK JL, FLORIO AA, KOSHIOL J, et al. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies[J]. Int J Cancer, 2020, 147( 10): 2743- 2753. DOI: 10.1002/ijc.33051.
    [11]
    LI YY, LI JJ, SHI HF, et al. Advances in imaging research on source identification of primary liver metastases[J]. J Clin Radiol, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007.

    黎玉莹, 李晶晶, 石海峰, 等. 肝转移瘤原发灶来源鉴别的影像学研究进展[J]. 临床放射学杂志, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007.
    [12]
    JIA W, WEI ML, RAJANI C, et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases[J]. Protein Cell, 2021, 12( 5): 411- 425. DOI: 10.1007/s13238-020-00804-9.
    [13]
    LI TG, CHIANG JYL. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev, 2014, 66( 4): 948- 983. DOI: 10.1124/pr.113.008201.
    [14]
    WANG CZ, YANG MY, ZHAO JF, et al. Bile salt(glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234( 7): 10899- 10906. DOI: 10.1002/jcp.27905.
    [15]
    MA C, HAN MJ, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360( 6391): eaan5931. DOI: 10.1126/science.aan5931.
    [16]
    SARKAR J, AOKI H, WU RR, et al. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis[J]. Ann Surg Oncol, 2023, 30( 3): 1630- 1641. DOI: 10.1245/s10434-022-12806-4.
    [17]
    CHENG P, WU JW, ZONG GF, et al. Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver[J]. Pharmacol Res, 2023, 188: 106643. DOI: 10.1016/j.phrs.2022.106643.
    [18]
    HAN J, QIN WX, LI ZL, et al. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Clin Chim Acta, 2019, 488: 68- 75. DOI: 10.1016/j.cca.2018.10.039.
    [19]
    LUO P, YIN PY, HUA R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma[J]. Hepatology, 2018, 67( 2): 662- 675. DOI: 10.1002/hep.29561.
    [20]
    XIAN LF, FANG LT, LIU WB, et al. Epidemiological status, main pathogenesis and prevention and control strategies of primary liver cancer[J]. Chin J Oncol Prev Treat, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13.

    鲜林峰, 方乐天, 刘文斌, 等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13.
    [21]
    The Society of Liver Cancer, China Anti-Cancer Association. CACA guidelines for holistic integrative management of cancer-liver cancerpart[J/CD]. J Multidiscip Cancer Manag Electron Version, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.

    中国抗癌协会肝癌专业委员会. 中国肿瘤整合诊治指南(CACA)-肝癌部分[J/CD]. 肿瘤综合治疗电子杂志, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.
    [22]
    TIAN CX, ZHAO L. Epidemiological characteristics of colorectal cancer and colorectal liver metastasis[J]. Chin J Cancer Prev Treat, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12.

    田传鑫, 赵磊. 结直肠癌及结直肠癌肝转移流行病学特点[J]. 中华肿瘤防治杂志, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12.
    [23]
    WANG ZJ, KIM SY, TU W, et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment[J]. Cell Metab, 2023, 35( 7): 1209- 1226. e 13. DOI: 10.1016/j.cmet.2023.04.013.
    [24]
    XIAO JF, VARGHESE RS, ZHOU B, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J]. J Proteome Res, 2012, 11( 12): 5914- 5923. DOI: 10.1021/pr300673x.
    [25]
    ZENG HW, UMAR S, RUST B, et al. Secondary bile acids and short chain fatty acids in the colon: A focus on colonic microbiome, cell proliferation, inflammation, and cancer[J]. Int J Mol Sci, 2019, 20( 5): 1214. DOI: 10.3390/ijms20051214.
    [26]
    LI JY, GILLILLAND M 3rd, LEE AA, et al. Secondary bile acids mediate high-fat diet-induced upregulation of R-spondin 3 and intestinal epithelial proliferation[J]. JCI Insight, 2022, 7( 19): e148309. DOI: 10.1172/jci.insight.148309.
    [27]
    CHEN TL, XIE GX, WANG XY, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Mol Cell Proteomics, 2011, 10( 7): M110.004945. DOI: 10.1074/mcp.M110.004945.
    [28]
    COLLINS SL, STINE JG, BISANZ JE, et al. Bile acids and the gut microbiota: Metabolic interactions and impacts on disease[J]. Nat Rev Microbiol, 2023, 21( 4): 236- 247. DOI: 10.1038/s41579-022-00805-x.
    [29]
    ZHANG YF, LI MC. Application value of chitosanase 3-like protein 1, alpha-fetoprotein, glycoactrin 19-9, glutamyltranspeptidase in the early diagnosis of primary liver cancer[J]. Chin J Health Lab Technol, 2023, 33( 4): 467- 470.

    张艳芬, 李明才. 血清壳多糖酶3样蛋白1、甲胎蛋白、糖类抗原19-9及谷氨酰转肽酶在原发性肝癌早期诊断中的应用价值[J]. 中国卫生检验杂志, 2023, 33( 4): 467- 470.
    [30]
    YANG YP, XU EJ, WANG XX, et al. The value of GNB4 and Riplet gene methylation detection in the diagnosis of primary liver cancer[J]. Acta Univ Med Anhui, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028.

    杨玉萍, 徐恩君, 汪轩轩, 等. GNB4和Riplet基因甲基化检测在原发性肝癌诊断中的价值研究[J]. 安徽医科大学学报, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028.
    [31]
    ZHANG JL, SHEN Q, WANG N, et al. Values of serum 7 microRNAs alone or in combination with α-fetoprotein in diagnosing hepatocellular carcinoma[J]. Acad J Nav Med Univ, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648.

    张敬磊, 沈强, 王能, 等. 血清7种微RNA单独或联合甲胎蛋白检测对肝细胞癌的诊断价值[J]. 海军军医大学学报, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (342) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return